跳至主要内容
临床试验/NCT01059994
NCT01059994已完成不适用

Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability

The University of Texas Medical Branch, Galveston1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
12
试验地点
1
主要终点
Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil

研究概览

简要总结

This is a pilot study funded by the National Institutes of Health. In this project, we will investigate the potential effect of skeletal muscle nitric oxide (NO) production on muscle strength and physical function in older individuals. We propose to test a new method that may enable simultaneous determination of both vascular and skeletal muscle NO production for the first time in humans. Further, we will determine whether augmentation of NO-mediated responses, by administration of sildenafil citrate (Viagra), reduces fatigue and fatigability in older individuals.

详细描述

Fatigue is highly prevalent and associated with future mortality in older individuals. Even in non-disabled older persons, fatigue may be the primary reason for activity limitation. However, understanding the etiology of fatigue in this population has been hampered by differing or imprecise definitions of fatigue. As a result, the term fatigue has been proposed to refer to the subjective experience of tiredness or lack of energy, whereas the term fatigability should refer to the susceptibility to fatigue induced by activity of any kind (mental, physical, etc). Skeletal muscle activity can contribute to the perception of overall fatigue as well as produce a type of localized fatigue within skeletal muscle. Skeletal muscle fatigue is defined as a decline in skeletal muscle performance resulting from muscle activity.

We hypothesize that skeletal muscle NO-mediated responses are reduced with aging due to decreased skeletal muscle NO production. NO is well-known to elicit vasodilation through stimulation of cGMP signaling, and NO-mediated changes in muscle perfusion may influence both skeletal muscle and overall fatigue. To measure skeletal muscle NO production, we will infuse a stable isotope tracer of arginine, the precursor of NO, and measure its conversion across the leg and in skeletal muscle to citrulline (which is another product of the reaction that produces NO). If successful, this method will allow the study of relative changes in vascular and muscle NO production that occur with aging and other conditions (e.g., hypertension, Duchenne muscular dystrophy). We will also determine whether age-related differences in muscle perfusion and NO-cGMP signaling exist between younger and older groups. As impaired redox homeostasis and ryanodine receptor S-nitrosylation and phosphorylation have been implicated in skeletal muscle fatigue, we will assess skeletal muscle redox homeostasis and ryanodine receptor S-nitrosylation in these experiments. We hypothesize that aging will shift muscle redox homeostasis to a more oxidized state.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Age 20-35 yrs, and 60-80 yrs.
  • Ability to sign consent form (score >23 on the 30-item Mini Mental State Examination, MMSE)
  • Stable body weight for at least 3 months

排除标准

  • Physical dependence or frailty (impairment in any of the Activities of Daily Living (ADL), history of falls (>2/year) or significant weight loss in the past year)
  • Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
  • Significant heart, liver, kidney, blood or respiratory disease
  • Peripheral vascular disease
  • Diabetes mellitus or other untreated endocrine disease
  • Active cancer
  • Use of nitrates
  • Recent (within 6 months) treatment with anabolic steroids, or corticosteroids.
  • Alcohol or drug abuse
  • Severe depression (>5 on the 15-item Geriatric Depression Scale, GDS)
  • Cardiac abnormalities such as a cardiac shunt or previously diagnosed pulmonary hypertension.
  • Systolic blood pressure <100 or >150, diastolic blood pressure <60 or >90.

研究组 & 干预措施

placebo sildenafil young

Placebo Comparator

Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.

干预措施: Placebo sildenafil (Drug)

sildenafil young

Experimental

Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.

干预措施: Sildenafil (Drug)

placebo sildenafil older

Placebo Comparator

Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.

干预措施: Placebo sildenafil (Drug)

sildenafil older

Experimental

Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.

干预措施: Sildenafil (Drug)

结局指标

主要结局

Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil

时间窗: baseline to 1 week

Muscle fatigue was tested before and after 1 week of placebo/sildenafil (25mg/day) treatment. Subjects were asked to perform maximum effort isokinetic knee extensions until force production reached 50% of their MVC (maximum voluntary contraction). Data was collected as number of successful repetitions completed between start and 50% MVC. Data is presented as percent change in repetitions (1 week of treatment / baseline).

次要结局

  • Protein Synthesis Rate After 1 Week of Sildenafil or Placebo(1 week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验